District Of Columbia is currently home to 850 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT03474029
Recruiting
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection (LTBI). This trial is conducted among persons who are at increased risk of progression to tuberculosis (TB) and require treatment of LTBI. The study will be conducted in low, medium and high TB incidence settings that have t... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
09/25/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Latent Tuberculosis
Register for Updates
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
NCT03827694
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Register for Updates
Consent for Use of Stored Patient Specimens for Future Testing
NCT00031408
Recruiting
The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.
Gender:
ALL
Ages:
All
Trial Updated:
09/20/2024
Locations: Georgetown Univ Med Ctr, Washington, District of Columbia
Conditions: HIV Infections
Register for Updates
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795
Recruiting
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: Site USA06-0, Washington, D.C., District of Columbia
Conditions: Solid Tumor, Adult
Register for Updates
Cooperative Assessment of Late Effects for SCD Curative Therapies
NCT05153967
Recruiting
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened.... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
09/16/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Sickle Cell Disease, Pulmonary Disease, Renal Disease, Heart Disease
Register for Updates
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
NCT05674656
Recruiting
The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA \[Ribonucleic Acid\] \< 50 \[cells per milliliter\] c/mL) children 6 to less than 12 years of age, weighing at least 25 kilogram (kg).
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
09/13/2024
Locations: GSK Investigational Site, Washington, District of Columbia
Conditions: HIV Infections
Register for Updates
Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their CART and Have Dual- or Triple-class Antiretroviral Resistance
NCT04648280
Recruiting
In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance. It will also assess the acceptability and swallowability of formulation among the pediatric population. The dose selection of FTR for children and adolescents ≥20kg utilized a population pharmacokinetic (POP PK) model-based approach to achieve similar adult TMR exposures following FTR 600mg BID administration with combination therapy that was... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
09/04/2024
Locations: The George Washington University, Children's National Health System, Washington, District of Columbia
Conditions: HIV Infections With Multi Drug Resistant Virus
Register for Updates
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
NCT01694940
Recruiting
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
Gender:
ALL
Ages:
All
Trial Updated:
09/03/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Register for Updates
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT05870748
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
Register for Updates
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
NCT03594981
Recruiting
This Phase I-II dose-finding trial to determine the optimal dose of intravenous (IV) injection dose of donor-derived cytotoxic T lymphocytes (CTLs) specific for CMV, EBV, BKV and Adenovirus. A maximum of 36 patients will be treated in up to 18 cohorts each of size 2, with the first cohort treated at the lowest dose level 1, all successive doses chosen by the EffTox method, and no untried dose level skipped when escalating. The scientific goal of the trial is to determine an optimal IV-CTL cell... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/27/2024
Locations: Children's National Health System, Washington, District of Columbia
Conditions: Viral Infection
Register for Updates
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
Recruiting
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonar... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/23/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Register for Updates